What is MaxCyte's G&A?

MaxCyte (MXCT) reported G&A of $5.97M in Q1 2026.

How has MaxCyte's G&A changed year-over-year?

MaxCyte's G&A decreased by 30.0% year-over-year, from $8.53M to $5.97M.

What is the long-term trend for MaxCyte's G&A?

Over 4 years (2021 to 2025), MaxCyte's G&A has grown at a 10.8% compound annual growth rate (CAGR), from $18.68M to $28.12M.

Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

MaxCyte MXCT G&A

G&A at other companies

Ginkgo BioworksDNA

$37.83M-4.8%

Immix Biopharma, Inc.IMMX

$4.82M+78.1%

Rapid Micro BiosystemsRPID

$7.44M+30.8%

Prime MedicinePRME

$17.41M+31.0%

Segments

By segment

See full

Cell Engineering Technology$5.23M-22.0%

Other financials

Income statement

See full

Revenue$9.7M-7.1%

Gross profit$8.1M-9.1%

Operating income-$6.2M+49.7%

Net income-$4.8M+53.7%

EPS (diluted)-$0.04+60.0%

Balance sheet

See full

Cash & equivalents$14.6M-37.8%

Total debt$17.5M-7.1%

Total equity$167.9M-15.8%

Total assets$194.5M-15.4%

Cash flow

See full

Operating cash flow-$8.2M+43.3%

CapEx$72.0K-89.0%

Free cash flow-$8.2M+45.3%

Valuation

See full

Market cap$130.15M-46.8%

Enterprise value$133.08M-46.3%

P/S4×-2.8×

Profitability

See full

Gross margin80.5%-0.4pp

Operating margin-141.8%+6.4pp

Net margin-121.2%+12.3pp

FCF margin-90.9%+3.7pp

Returns & leverage

See full

Return on equity-21.3%+2.0pp

Debt / equity0.1×0.0×

Current ratio12×-0.2×

Where this comes from

Reported directly by MaxCyte in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: MaxCyte’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about MaxCyte's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is MaxCyte's G&A?: MaxCyte (MXCT) reported G&A of $5.97M in Q1 2026.
How has MaxCyte's G&A changed year-over-year?: MaxCyte's G&A decreased by 30.0% year-over-year, from $8.53M to $5.97M.
What is the long-term trend for MaxCyte's G&A?: Over 4 years (2021 to 2025), MaxCyte's G&A has grown at a 10.8% compound annual growth rate (CAGR), from $18.68M to $28.12M.
What does G&A mean?: Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.